)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Knight Therapeutics
Knight Therapeutics (GUD) investor relations material
Knight Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Record nine-month revenue reached CAD 430.3M, up 36% YoY, and Adjusted EBITDA was CAD 76.3M, up 57% YoY.
FY26 guidance was raised, and peak annual revenue potential for pipeline and launched pipeline products increased to over CAD 300M.
Financial highlights
Q3 revenue was CAD 137.7M, up 13% reported; Adjusted Revenue excluding IAS 29 was CAD 136.7M, with 4% constant-currency growth.
Q3 Adjusted EBITDA was CAD 23.8M, up 13% YoY; nine-month Adjusted EBITDA was CAD 76.3M, up 57%.
Q3 IFRS gross margin was CAD 68.4M versus CAD 55.8M; operating loss was CAD 6.6M versus operating income of CAD 0.6M, and net loss narrowed to CAD 2.7M from CAD 3.8M.
Nine-month IFRS net income was CAD 7.1M versus a CAD 14.2M net loss in the prior-year period.
Outlook and guidance
FY26 revenue guidance increased to CAD 560M–CAD 570M from CAD 540M–CAD 560M; Adjusted EBITDA is expected at ~17.5% of revenue, up from at least 15%.
Peak annual revenue potential for pipeline and launched pipeline products rose to over CAD 300M from over CAD 200M, reflecting product performance and Poteligeo; more than 75 products are covered, with 22 launched.
Guidance assumes successful launch uptake and commercial listings, no key-brand generic entrants or supply interruptions, and no material adverse pricing, FX, inflation, tariff or geopolitical changes.
Management expects margins to remain near current levels for the next couple of years and then expand as launches contribute; 2024–25 launches are expected to reach peak sales in 4–5 years.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Knight Therapeutics
- Record H1 2026 revenue and EBITDA growth led to raised guidance and strong launch momentum.GUD
Q2 2026 - Record Q1 2026 results and raised outlook reflect strong product growth and portfolio expansion.GUDQ1 2026
- Record 2025 results, new acquisitions, and strong growth plans approved by shareholders.GUDAGM 2026
- Rapid growth through acquisitions and launches, with a strong pipeline and financial position.GUDInvestor presentation
- Record revenue and EBITDA in 2025, with strong growth from acquisitions and new launches ahead.GUDQ4 2025
- Record revenue growth and portfolio expansion drive higher 2025 outlook and stable margins.GUDQ2 2025
- Record revenues and raised 2024 guidance highlight strong product-driven growth.GUDQ2 2024
- Exclusive Canadian rights to six pharma assets boost growth, with impact accelerating in 2026.GUDM&A Announcement
- Record 2024 revenue and pipeline growth, with Paladin acquisition to drive 2025 expansion.GUDQ4 2024
Next Knight Therapeutics earnings date
Q4 202618 Mar, 2027
Knight Therapeutics
Next Knight Therapeutics earnings date
Q4 202618 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Knight Therapeutics Inc is a Canadian specialty pharmaceutical company that acquires, licenses, and commercializes prescription medicines for the Canadian and Latin American markets. The company focuses on late-stage or commercial products across therapeutic areas such as oncology, infectious diseases, and ophthalmology. Knight Therapeutics Inc is headquartered in Montreal, Canada, and its shares are listed on the TSX.